AaviGen is a pre-clinical biotech company developing gene therapies for genetic and acquired cardiovascular and cardiopulmonary diseases. Its lead program uses heart-specific recombinant Adeno-Associated Viruses (AAV) to deliver therapeutic genes with exceptional safety and precision to the heart via a one-time intravenous injection. AaviGen’s program builds on the expertise of its interdisciplinary leadership team, combining expertise in clinical cardiology, pneumology, virology, genetic vector engineering, and gene therapy product development.

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.

AcademicLabs.com is a leading solution for scientific landscaping and expert identification. It helps Business Development, Search & Evaluation, External Innovation, Competitive Intelligence teams, and R&D leadership understand who is working on what and with whom in any field. It systematically identifies collaborators, KOLs, rising stars, startups, academic partners, and R&D activities from pharma, literature, research, projects, trials, and patents. Life science service providers use it to quickly find targeted customers and champions in pharma, biotech, and academia.

ACROBiosystems is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business model innovation. They offer a wide array of life sciences tools, reagents, and instruments to serve customers spanning over 7000 pharmaceuticals, CRO/CDMO, research institutions, and hospitals across 70 countries.

Actome GmbH, a startup recognized by the European Innovation Council, is advancing protein analysis. Based in Freiburg, it developed PICO (Protein Interaction Coupling) Technology, allowing scientists to analyze proteins, interactions, and modifications with high throughput, enhancing research efficiency. Actome recently expanded its tools to include extracellular vesicle analysis and is developing a method for absolute protein quantification in single cells with EIC support, pushing cellular analysis boundaries.

Affimed is a clinical-stage biopharma company focused on restoring patients’ innate ability to fight cancer. Its ROCK® platform designs immune engagers for specific populations, developing single and combination therapies for cancer. Several clinical and preclinical programs are in progress, with Affimed’s tetravalent bispecific immune cell engagers showing a favorable safety profile and promising therapeutic efficacy.

AGC Biologics offers deep industry expertise and uniquely customized services for the scale-up and cGMP manufacture of protein-based therapeutics, from pre-clinical to commercial production, using mammalian and microbial production systems. The company’s integrated service offerings include cell line development, bioprocess development, formulation, analytical testing, antibody drug development and conjugation, cell banking and storage and protein expression.

AnaBioTec provides analytical insight during CMC activities for your product development & filing. With more than 20 years of experience in analytical method development and validation they help you mitigating risk and accelerating timelines. Their experienced scientific project managers connect the dots in your projects and anticipate where needed and safeguard your milestones.

Anavo Therapeutics is pioneering the drugging of phosphatases, a target space long considered undruggable. With leading expertise in phosphatase-driven disease biology and drug discovery, Anavo is developing first-in-class oncology therapies and building partnerships to expand its pipeline across multiple indications. The company is backed by blue-chip investors, including M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures.

Aomics GmbH is spearheading a revolution in healthcare through cutting-edge immuno-oncology research. As a company centered on immuno-informatics and clinical data science, they offer extensive services in statistical consulting, statistical programming, and bioinformatics, specifically tailored for healthcare initiatives. Aomics’ expertise is particularly concentrated in the domain of Immuno-Oncology research studies.

Apogenix has developed a portfolio of immuno-oncology therapeutics for cancer and other diseases, targeting TNFSF-dependent signaling pathways to restore the anti-tumor immune response. Its lead candidate, asunercept, is in late-stage development for recurrent glioblastoma, an aggressive brain tumor. Apogenix’s proprietary HERA-ligand platform enables novel fusion protein development. In 2017, AbbVie launched a phase I trial of the HERA-TRAIL receptor agonist (ABBV-621) for solid tumors, lymphoma, and leukemia.

Arcondis is a global consulting company focused exclusively on healthcare and life sciences. Since 2001, they’ve helped partners tackle compliance, business processes, IT, and digital transformation challenges. They offer customized, 360-degree services to address operational and strategic issues for clients, from large global brands to small startups. Using cross-functional delivery methodologies, they partner worldwide to improve healthcare. In 2021, Statista ranked Arcondis among Switzerland’s Top 10 Healthcare consultancies.

Ardigen is a world-leading AI CRO, driving AI transformation in biotech and pharmaceuticals to increase success in drug development. Positioned at the intersection of biology and computational science, they use advanced platforms and expertise to turn vast data into ready-to-use insights, helping find therapeutic targets, optimize molecules, and advance biologics. Ardigen also enhances infrastructure, offering data engineering, processing, and management solutions, empowering companies and shaping the future of AI-driven biopharma.

Ariadne.ai AG is a CRO specializing in automated high-throughput biomedical image analysis and cutting-edge image processing technology. Scalable and consistent, they accelerate research by addressing image processing bottlenecks, allowing teams to focus on staining and imaging. Whether automating existing workflows or creating new ones, they enable experiment scaling. Their interdisciplinary team combines human and AI expertise to transform imaging data into quantitative results, developing AI-powered biomarkers to extract revolutionary insights from biomedical images.

Ascendis Pharma uses its innovative TransCon™ technology to build a leading biopharma company focused on improving patients’ lives. Driven by core values of patients, science, and passion, they are developing new therapies, with a pipeline of three rare disease endocrinology candidates in clinical development and oncology as their second focus. They also have collaborations with Sanofi in diabetes and Genentech in ophthalmology. Ascendis is headquartered in Copenhagen, with offices in Heidelberg and Palo Alto.

Bayer is a global life science company specializing in healthcare and nutrition, operating in crop science, pharmaceuticals, and consumer health. The Crop Science segment focuses on seeds, plant traits, crop protection, and digital solutions for sustainable agriculture. The Pharmaceuticals segment offers prescription products for cardiology, women’s health, oncology, hematology, ophthalmology, and diagnostic imaging. The Consumer Health segment provides nonprescription medicines, supplements, and self-care products for dermatology, pain, cardiovascular, and digestive health.

BD is a global medical technology company advancing health through medical discovery, diagnostics, and care delivery. It leads in patient and healthcare worker safety, offering solutions that enhance medical research, genomics, infectious disease and cancer diagnostics, medication management, infection prevention, surgical procedures, and diabetes care. With over 65,000 associates across 50 countries, BD partners globally to improve outcomes, lower healthcare costs, enhance safety, and expand access to health.

BioCat GmbH, based in the Heidelberg Technology Park near the German Cancer Research Center, was founded in 2000 to market innovative life science research products and services. BioCat offers a wide range of high-quality reagents, instruments, and cutting-edge technologies in genomics, proteomics, and cell biology for academia and the pharma/biotech industry. Their Ph.D.-level scientists provide expert support, ensuring superior product performance for fast, reliable results. Products are developed by partners in Canada, Europe, and the USA.

BIMOVIS supports small and medium-sized companies in structural biology through consulting, training, and project coordination. While large companies have dedicated departments for drug design, protein engineering, and analytical methods, it’s often uneconomical for startups and SMEs to employ structural biologists, creating a disadvantage. BIMOVIS bridges this gap, offering tailored training and expertise to help companies become more independent and proficient in structural biology and protein science.

Biocrates is the world’s leading company for targeted mass spectrometry (MS)-based metabolite analysis, with over 1000 metabolites from more than 30 metabolite classes. Our technology combines innovative technology for sample preparation, metabolite identification and data analysis. Metabolomics is a powerful tool to answer a vast number of biological questions, from just a few microliters of sample material. The use of quantitative, standardized, and quality-controlled methods guarantees robust and reproducible results, which is essential for true scientific progress.

BioKryo is a biorepository focused on the storage of biological samples in temperatures ranging from -196°C in liquid nitrogen in cryotanks to -80°C, -20°C and 4°C in freezers. Their goal is to support biotechnology/pharmaceutical companies in their manufacturing process by providing a safe, redundant and qualified storage of their biological samples. Some examples of samples stored in their locations are cell lines, antibodies, ADCs, vaccine products, transplants, clinical trial samples (blood, serum, plasma). In addition, they offer logistic coordination of received and shipped samples through their qualified and validated partners.

BioLabs are the premier co-working spaces for life science startups — unique places where you can test, develop and grow your game-changing ideas. As entrepreneurs and investors ourselves, we have firsthand experience with the pain points biotech startups face. Our goal is to change how scientific entrepreneurs do business by building an ecosystem that empowers bioinnovators to grow quickly, while maximizing capital efficiency.

BioMed X, an independent research institute on the University of Heidelberg campus, tackles major biomedical challenges through global crowdsourcing and local incubation of top early-career researchers. Each team has access to state-of-the-art infrastructure and is guided by experienced mentors. BioMed X merges academia and industry to make biomedical research more efficient, agile, and enjoyable, fostering breakthrough innovation.

Founded in 1997 in BioRegio Rhein Neckar near Heidelberg, BioRepair collaborates with universities and private institutes to offer diagnostic tools for parasitology, microbiology, and immunology. The company serves the German market through direct visits, key account management, phone marketing, mail shots, and media, with customers including universities, hospitals, labs, and veterinarians. BioRepair’s parasite concentration system is a leading product in Europe for detecting parasites, larvae, and eggs from stool samples.

BioThrust is a spin-off from RWTH Aachen University developing a next generation bioreactor for the efficient manufacturing of cell therapies and stem cells. The core of this bioreactor is BioThrust’s unique membrane aeration technology which for the first time enables an effective completely bubble-free aeration of cell cultivations. With this technology, cell yields can be increased by up to 200%. The bioreactor will be available in sizes 250mL to 2000L. The deep-tech start-up is based in Aachen, Germany

Boehringer Ingelheim is a research-driven pharmaceutical company focused on improving human and animal health, particularly for diseases lacking effective treatments. The company develops innovative therapies to extend patient lives and leads in animal health prevention. Founded in 1885, it remains family-owned and ranks among the top 20 pharma companies globally. With around 50,000 employees, Boehringer Ingelheim achieved €17.5 billion in sales in 2018, investing €3.2 billion in R&D. The company focuses on long-term growth, partnerships, and environmental responsibility.

BPL, Biotech & Pharma Logistics, specializes in transport and courier services for pharmaceuticals, biotechnology, life sciences, and medical technology. They handle customs formalities and regulatory affairs while offering customized, temperature-controlled logistics solutions worldwide. BPL’s packaging systems meet the demands of the global cold chain, including preconditioning, on-site packing, labeling, and compliance with dangerous goods regulations. BPL’s Quality Management System adheres to EU GDP Guidelines and is ISO 9001:2015 accredited.

btS – Life Sciences Studierendeninitiative e.V. is a student initiative that connects life sciences students and doctoral candidates across Germany. It aims to bridge the gap between students, universities, research institutes, and industry, fostering stronger connections in the field. By organizing local and national projects, btS broadens students’ horizons and provides valuable insights. Students benefit from a wide range of training and information opportunities, while employers can connect with potential employees and present themselves to a young professional audience.

cAHRmeleon Bioscience GmbH, a biotech spin-off from the German Cancer Research Center (DKFZ), is led by a team with extensive experience in immuno-oncology and cancer metabolism. The company developed AI-AHR technology, an AI-assisted platform targeting the Aryl Hydrocarbon Receptor (AHR) to identify modulators and analyze AHR functions in tumor immune evasion. cAHRmeleon discovered IL4I1 as a novel immune-suppressive drug target and created AHR profiles for cancer prognostic assays. Their approach combines AI-driven discovery with clinical validation to accelerate cancer drug development.

Celonic helps biotech customers deliver innovative biotherapeutics through comprehensive GMP development and manufacturing services for New Biological Entities (NBEs), Biosimilars, and Cell & Gene Therapy. Celonic goes beyond expectations to help clients achieve goals efficiently. Their services include cell line development, production processes, and non-GMP/GMP manufacturing of biopharmaceuticals. Utilizing CHOvolution™ and GEX® cell line technology, Celonic, part of JRS Pharma, fosters win-win partnerships to drive breakthrough developments from lab to market success.

Cogitars GmbH was founded in 2013. The main focus of the company is on statistical support for Biotech- and Pharma Companies including Bayesian trials in phase 1, ranging from technical implementation to protocol writing and negotation with regulators. Cogitars has specific expertise in the field and, where required, works with a network of international experts to provide best solutions to its customers

Since its foundation in 1978, Concept Heidelberg has focused on the pharmaceutical and biotech industries. As Europe’s leading provider of advanced training in pharmaceutical quality assurance and drug safety (GMP and GDP), they organize over 300 seminars and conferences across 10 European countries. Besides its own events, Concept Heidelberg also collaborates with institutions to offer training. They provide GMP/GDP services like in-house training, e-learning, and consulting to help clients maintain regulatory compliance.

CORAT Therapeutics GmbH develops innovative therapeutic drugs composed of novel fully human neutralizing antibodies against COVID-19. CORAT antibodies very efficiently neutralize SARS-CoV-2 and stop its spread within the human body. Our lead product, COR-101, decreased the virus load in the lung by more than 99 % in the hamster COVID-19 model, and induced recovery after 2 days, compared to 7 days untreated.

dAIgnosis is a young start-up, that aims to improve healthcare by offering faster and more precise cancer diagnostics. With the rise of cancer cases and a decreasing number of pathologists, the start-up addresses the increasing workload and long diagnosis times by providing access to digital technologies, including AI-based counselling. Their cost-per-test subscription model reduces barriers to adopting these innovations, ensuring quicker diagnosis and treatment for patients, which is crucial as cancer patients face significant time constraints.

Daiichi Sankyo’s European roots date back to the 1980s with branches in Düsseldorf. In 1990, Sankyo acquired Luitpold-Werke, a German pharmaceutical company, expanding operations to Pfaffenhofen, Germany, and Altkirch, France. In 2006, Daiichi and Sankyo merged, with European headquarters in Munich. Now present in 13 countries, Daiichi Sankyo employs over 2,000 people, making it one of Europe’s largest Japanese pharmaceutical companies. It develops and markets treatments for hypertension, dyslipidemia, infections, cardiovascular diseases, and thrombotic disorders.

DataHarmony Ltd is a pre-seed startup creating a novel platform for biomedical and life sciences researchers. Their cloud-based platform enables efficient, collaborative research, allowing public and private organizations to securely share datasets, applications, and analysis pipelines. The platform simplifies scientific collaboration and scales research with global collaboration zones, life science-optimized virtual machines, and top-tier security. DataHarmony aims to democratize advanced research technologies, making them accessible for scientists globally.

Deep LS helps (bio)pharmaceutical companies to accelerate their drug discovery process. With their AI de novo ligand design solution the customers are empowered to control the chemical space. They can generate small molecules and proteins that fit to their target and meet additional criteria, e.g. toxicity.

Intelsius is a global leader in designing and supplying temperature-controlled, regulatory-compliant packaging for the life sciences industry. For over 20 years, they have helped customers achieve better patient outcomes. Intelsius offers a range of sample transport solutions for biological and pharmaceutical materials, ensuring integrity with precise, ISTA-certified packaging systems. Their global locations provide local support for safe specimen transport and flexibility when time is critical.

With Docuply, we enable pharmaceutical and biotech companies to ensure smooth and secure quality management with third parties and distributed teams. This allows you to avoid chaotic audits and downtime during an inspection. Ultimately, this leaves more time for what really matters: Making the world a little bit better with new medicines. The Quality Management System for pharmaceutical SME and Start-ups.

The European Molecular Biology Laboratory (EMBL) is a leading research institution and Europe’s flagship for life sciences. Funded by over 20 member states and two associate members, EMBL operates six sites: Heidelberg (main lab), Hinxton (Bioinformatics), Grenoble (structural biology), Hamburg (structural biology), Rome (epigenetics), and Barcelona (tissue biology). EMBL focuses on basic research, advanced training, and technology development in life sciences. Their mission is to lead in research, provide top-tier training, and offer services to the scientific community.

Founded in 1999, EMBLEM is the technology transfer partner of the European Molecular Biology Laboratory (EMBL). Located at EMBL’s headquarters in Heidelberg, EMBLEM manages intellectual property from EMBL’s sites in Heidelberg, Hinxton, Hamburg, Grenoble, Rome, and Barcelona. They handle over 900 inventions, 300+ patent applications, and 400+ active licenses with key players in pharma, biotech, and instrumentation. EMBLEM’s technology portfolio includes life sciences technologies, molecular tools, instruments, and software.

EUDRAC, based in Germany, France, and the UK, is a European regulatory affairs and pharmacovigilance consultancy. Since 2002, it has supported pharmaceutical and medical device companies through development, registration, market launch, and post-approval across all EU countries. EUDRAC’s experienced team includes pharmacists, chemists, biologists, a medical doctor, and regulatory specialists. The company’s extensive expertise spans various therapeutic areas and pharmaceutical forms, with a high level of repeat business reflecting its excellent service.

The European Vaccine Initiative (EVI) supports vaccine candidates for diseases of poverty emerging from European labs. It funds early-stage development, unites major EU organizations in vaccine R&D, and coordinates global research consortia to accelerate the development of safe, effective, and affordable vaccines.

Evotec is a global leader in drug discovery and development partnerships, collaborating with pharmaceutical, biotech companies, and academia. With over 2,900 employees, it provides comprehensive solutions from target discovery to clinical development (EVT Execute). Specializing in areas like oncology, diabetes, and neurological diseases, Evotec manages about 100 co-owned products in various stages. The company maintains long-term partnerships with major industry players such as Bayer, Novartis, and Pfizer (EVT Innovate).

faCellitate, an SME with strong R&D and entrepreneurial expertise, develops polymer surface coatings for cell-based assays used in cancer, stem cell research, and drug development. Their first product, the BIOFLOAT™ pre-coated 96-well plate, launched in 2020, enables reliable 3D spheroid formation. Other products include the BIOFLOAT™ pre-coated 384-well plates and BIOFLOAT™ FLEX, a versatile coating solution. A spin-out from Chemovator GmbH (BASF SE), faCellitate secured €3.7 million in funding in 2022.

Forever Healthy is a non-profit humanitarian initiative with the mission of enabling people to vastly extend their healthy lifespan. Forever Healthy’s projects include the evaluation of new rejuvenation therapies, evidence-based curation of the world’s cutting-edge medical knowledge, funding translational research on the root causes of ageing, and hosting both the annual Undoing Aging Conference and the Rejuvenation Startup Summit.

Forvis Mazars Rechtsanwaltsgesellschaft mbH is a leading international audit, tax, and advisory firm. It provides advice on medical devices, health care apps, and in vitro diagnostics through interdisciplinary teams of lawyers, tax advisors, auditors, and IT security consultants. Trusted by universities, clinics, associations, and government bodies, the firm operates globally through Forvis Mazars Group SC, with over 35,000 professionals in more than 100 countries. In Germany, Forvis Mazars employs over 2,500 people across twelve locations, with an annual turnover of 283 million euros.

Fraunhofer IGB develops and optimizes processes, plants, products, and technologies in health, chemistry, the process industry, environment, and energy. Combining scientific excellence with practical know-how, IGB delivers economic, efficient, and sustainable solutions. Its research includes medical devices, food processing, water technologies, and biobased chemicals. IGB collaborates with academia and industry, covering the entire innovation chain from research to industrial implementation. It is one of 72 institutes of the Fraunhofer-Gesellschaft.

Fraunhofer IPA, one of the largest Fraunhofer-Gesellschaft institutes, was founded in 1959 and employs nearly 1,200 workers. It focuses on organizational and technological issues in sectors such as automotive, machinery, electronics, energy, medical engineering, and biotechnology. The “Clinical Health Technologies” department drives innovation in medicine and biotechnology. IPA forms networks, collaborates with the University Medical Center Mannheim and start-ups, and brings new ideas directly to the clinic. It is a key partner in the Rhine-Neckar region and beyond.

Gemini PharmChem Mannheim GmbH, a major R&D site in Mannheim, Germany, operates under Synbias Pharma AG, Switzerland. It specializes in highly potent APIs for cancer therapies, including Anthracyclines, Nucleosides, and Plant Alkaloids. A leading global supplier of anthracycline antibiotics, it holds a 30-50% market share. Annually, Gemini PharmChem ships about 300 kg of APIs to 21 countries. Its Quality System meets Swissmedic, cGMP, and FDA standards. The company is known for its competence and innovative approach.

GenCC GmbH focuses on using CRISPR/Cas for cancer therapy. With advances in gene editing and tumor profiling, personalized cancer therapy is gaining attention. The project’s theoretical framework is developed, with initial proof-of-concept experiments planned for B-cell lymphomas in a level 1 security lab. This phase does not involve cancer stem cells. Following successful initial results and payment, the project will advance to further therapy and research questions.

Genius Search is a leading personnel consultancy specializing in life sciences, focusing on management and supervisory board placements. Their team of Life Science and Health Care experts brings years of experience and knowledge of key industry figures. They advise global players, medium-sized companies, investors, and family offices, offering services including executive search, coaching, and talent pipelining. Genius Search values discretion, trust, and commitment in their work.

GenScript Biotech (Netherlands) B.V. is a leading life sciences research and application service and product provider that applies its proprietary technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions.

GenScript ProBio, a subsidiary of GenScript Biotech Corporation, provides end-to-end CDMO services from drug discovery to commercialization. They specialize in CGT, antibody, and recombinant protein drugs, aiming to accelerate drug development. With facilities in the US, Netherlands, South Korea, and China, ProBio has supported over 90 IND approvals since October 2017. Their services include CMC for plasmids, viral vectors, mRNA vaccines, and nucleic acids, as well as therapeutic antibody discovery and biologics CDMO. ProBio’s goal is to reduce R&D costs and expedite drug development.

The German Cancer Research Center (DKFZ) is Germany’s largest biomedical research institute with over 3,000 employees. Its scientists focus on cancer development, risk factors, and strategies for prevention, diagnosis, and treatment. They manage the Cancer Information Service (KID) for patient and public information. In partnership with Heidelberg University Hospital, DKFZ established the National Center for Tumor Diseases (NCT) and contributes to the German Consortium for Translational Cancer Research (DKTK). DKFZ is funded mainly by the German Federal Ministry of Education and Research.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. GSK aims to positively impact the health of 2.5 billion people over the next 10 years. GSK’s bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. GSK is a company where outstanding people can thrive.

GUIDED Development GmbH, founded in 2014 by Rico Laage in Heidelberg, specializes in flexible support, service, and consulting for clinical development of therapeutics. They cater to small biotech firms, startups, and investigator-sponsored trials. GUIDED Development offers hands-on solutions for preclinical and clinical development challenges, providing access to a network of specialists and assisting in selecting and managing service partners, investigators, and CROs. They operate according to ICH-GCP standards and help set up minimal QM systems tailored to clients’ needs.

Gyros Protein Technologies AB, formed from the merger of Gyros AB (2000) and Protein Technologies Inc. (1985), supports biomolecule performance and productivity across research, drug discovery, and bioprocess applications. As a leader in peptide synthesis and bioanalysis, Gyros Protein Technologies accelerates the development of safer biotherapeutics. Their Gyrolab platform automates immunoassays at nanoliter scale, enhancing productivity with reproducible microfluidics and parallel processing, thus simplifying workflows and delivering high-quality data efficiently.

Heidelberg ImmunoTherapeutics GmbH, founded in 2016 as a spin-off from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital, is a clinical-stage biopharmaceutical company. It focuses on developing innovative antibody-based immunotherapeutics for viral diseases and cancer. The company’s lead product, HDIT101, targets herpes simplex virus infections. After completing an initial human study on pharmacokinetics, safety, and tolerability, two Phase II studies are ongoing for HSV-2 and HSV-1 infections.

The Heidelberg Institute for Theoretical Studies (HITS), established in 2010 by Klaus Tschira and the Klaus Tschira Foundation, is a private, non-profit research institute. HITS focuses on basic research in natural sciences, mathematics, and computer science, particularly in processing, structuring, and analyzing complex data. Research spans molecular biology to astrophysics. HITS is supported by the HITS Stiftung, Heidelberg University, and Karlsruhe Institute of Technology (KIT), with funding from BMBF, DFG, and the European Union.

Heidelberg Pharma is a biopharmaceutical company specializing in oncology, developing novel antibody-drug conjugates (ADCs) for targeted cancer treatment. ADCs combine antibody specificity with toxin efficacy to kill cancer cells. The company’s technology includes Amanitin-based ADCs (ATACs), offering a new approach to overcoming drug resistance. Heidelberg Pharma is advancing candidates like HDP-101 for multiple myeloma and HDP-201, an exatecan-based ADC. The company uses a hybrid model, developing proprietary and collaborative ADC therapies.

Founded in 1386, Heidelberg University is Germany’s oldest university and a top research institution in Europe. Renowned for its excellence in research and teaching, the university excels in various disciplines, including humanities, law, social sciences, natural sciences, and medicine. It focuses on four interdisciplinary research areas: life sciences, material science, cultural dynamics, and regulation. Heidelberg University has a diverse student and researcher population, with significant international representation.

Heidelberg University Hospital is a medical center in Germany and Europe, renowned for excellence in patient care, research, and teaching. The hospital delivers innovative diagnosis and therapy for complex diseases with state-of-the-art equipment. Interdisciplinary cooperation ensures optimal treatment. It collaborates with partner research institutes to develop and swiftly implement new therapies. The Medical Faculty and hospital work together to train doctors and dentists, offering top-quality post-graduate training and prioritizing exceptional care in nursing and health profession programs.

HI-STEM gGmbH, a non-profit partnership between the German Cancer Research Center (DKFZ) and Dietmar Hopp Stiftung, conducts cutting-edge research on stem cells with a focus on translating findings into clinical applications. Established in 2008, HI-STEM develops novel diagnostic tools and therapies for leukemic, solid tumor, and metastatic disease stem cells. Located on DKFZ’s fourth floor, HI-STEM’s international team of over sixty scientists, led by Professor Dr. Andreas Trumpp, addresses three major research topics.

Hochschule Mannheim – Mannheim University of Applied Sciences aims to train highly-qualified, responsible graduates capable of implementing solutions. It maintains close dialogue with business and society to ensure practical, up-to-date programs. With a global outlook, the university promotes international and cultural exchange and focuses on international community demands. For over 100 years, Hochschule Mannheim has adapted to educational needs with innovative concepts, fostering a respectful and open atmosphere among students, employees, and professors.

Homo Novus has over 20 years of experience in laboratory services, offering tailored solutions for individual needs. Their 300 square meter lab, qualified under EU GMP with clean rooms from grade D to A, provides services such as production, small batch filling under aseptic conditions, terminal sterilization, and contract R&D. Their skilled team ensures flexible and reliable solutions to meet specific requirements.

Health Research Services (HRS) Ltd, founded in 2000, operates in the UK, Germany, Moscow, Kiev, and Warsaw. As an independent CRO, HRS offers specialized services in consulting, scientific drug R&D, project management, clinical monitoring, medical writing, and regulatory affairs. With over two decades of experience, HRS turns basic research into marketed medications, providing Phase I-IV clinical trial solutions across various therapeutic areas. The company has conducted clinical trials in Central and Eastern Europe, including Germany, Russia, Ukraine, and Poland, and expanded to Hungary, Lithuania, Latvia, Estonia, and Bulgaria.

HS Analysis provides tissue analysis software for digital pathology and microscopy using advanced AI and deep learning. Their solutions automate image quantification, enhancing data quality and reproducibility while minimizing human errors. This system enables fast Big Data analysis, helping researchers meet high efficiency and output demands. HS Analysis collaborates with clients to develop modular and scalable software for histological studies. Established in the pharmaceutical industry, the company offers proven software solutions.

Hummingbird Diagnostics develops minimally invasive tests for early disease detection and health monitoring using blood and other liquid biopsies. The company focuses on microRNAs to enhance disease screening, diagnostics, and patient-specific prognostics. Their tests analyze disease-specific microRNAs to track disease onset, progression, and remission. Hummingbird aims to improve clinical outcomes by detecting serious conditions earlier. Their lead program for early lung cancer diagnosis is currently in clinical validation at top centers.

HWI offers comprehensive services for the pharmaceutical, biotech, and medtech industries, including Laboratory Services & Quality Control, Reference Standard Services, Vigilance & Quality Services, API Characterisation & Drug Development, and Regulatory Affairs & Life Cycle Management. Key competencies include complex development projects, new formulation development and dossier updates. HWI also provides clinical evaluation, biological safety assessment, technical documentation for medical devices, drug-device combinations, employing gap and risk analysis for strategic development.

Rhine-Neckar Chamber of Commerce and Industry (IHK) strongly supports the success of approximately 75,000 member companies. The IHK works for a competitive, open and innovative economy, so that the Rhine-Neckar metropolitan region gains further importance as a business location and improves its position in national and international competition.

InnovationLab GmbH specializes in printed and organic electronics, particularly flexible printed pressure sensors. They provide tailored print solutions for R&D challenges. InnovationLab collaborates with partners like BASF SE, SAP SE, Heidelberger Druckmaschinen AG, Karlsruhe Institute of Technology, and Heidelberg University to advance printed electronics. They offer R&D, pilot and industrial production, consulting, and facility management, supporting customers from initial ideas to industrial production. Heidelberger Druckmaschinen AG handles large-scale sensor printing.

INNOVECTIS, founded in 2000 as a subsidiary of Goethe University Frankfurt, excels in transferring academic knowledge to practical applications. Its business model supports unbureaucratic and practice-oriented technology transfer. INNOVECTIS leverages the expertise of Goethe University scientists to address industrial research challenges. Its business segments include patent management, commercialization, research and development projects, spin-offs, and scientific consulting.

Inova DE GmbH is an R&D company specializing in medical software and hardware development. Collaborating closely with medical professionals, Inova develops highly usable software for various applications, including oncology, hospital logistics, Ambient Assisted Living, orthopedic robots, and image-guided surgery solutions. With over five years of experience and adherence to DIN EN 62304 norms, Inova also offers innovation management services to support small and medium-sized companies in managing their projects.

The IKTZ Heidelberg is a non-profit transfusion medical service provider and blood donation center in the Heidelberg region. A joint venture of the Red Cross Blood Donor Service Baden-Württemberg Hessen and University Hospital Heidelberg, IKTZ supplies blood products, diagnostics, and therapeutic procedures to local clinics. Its Stem Cell Laboratory, operational since July 1, 2011, produces and stores stem cell preparations for the Heidelberg University Hospital’s transplantation program, aiding patients with bone marrow diseases.

io provides comprehensive consulting and planning services for the supply chain. Established in 1958, io supports clients from strategic planning to the execution of complex industrial projects. With expertise in production, logistics, SAP/IT, architecture, and project management, io delivers holistic solutions across the entire supply and value chain. Headquartered in Heidelberg, io also has offices in Berlin, Dortmund, Kaiserslautern, Leonberg, Leverkusen, Munich, Łódź, Bethlehem, Dubai, Hong Kong, and Singapore.

iQMedix aims to improve the lives of cancer patients by providing personalized treatments based on molecular analysis. Using liquid biopsies to determine gene expression profiles from circulating tumor cells, iQMedix enables doctors to tailor therapies to each patient’s unique cancer. Their approach offers precise insights to determine effective treatments. Their vision is to make cancer a manageable disease through personalized therapies, bringing hope and a cure to every patient by using advanced biotechnology to fully understand and outsmart cancer.

Isenbruck Bösl Hörschler is a leading German intellectual property law firm specializing in protecting intellectual property across chemistry, pharmaceuticals, biotechnology, medical engineering, physics, software, and engineering. The firm assists clients with new technologies and product launches. With offices in Mannheim, Munich, and Düsseldorf, it supports clients in maintaining and enforcing their intellectual property rights.

J&J Innovative Medicine, formerly Janssen Pharmaceutical Companies of Johnson & Johnson, reflects the company’s identity and mission more clearly. As part of Johnson & Johnson, it drives science-based innovations that address complex diseases and unlock future medicines. The diverse portfolio covers Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. The company is committed to developing treatments, finding cures, and supporting patients throughout their journey.

jtv plan provides services in project development, building project management, and architectural services, focusing on public, commercial, and industrial projects, especially in life sciences. The company has successfully developed research, laboratory, and production buildings for biotechnology, medical technology, and pharmaceuticals. With extensive experience in this regulated environment, jtv plan is a valuable partner for implementing complex projects.

KIT is “The Research University in the Helmholtz Association,” dedicated to creating and imparting knowledge for societal and environmental benefit. Its goal is to address global challenges in energy, mobility, and information. With about 9,300 employees across various disciplines and 25,100 students, KIT offers research-based programs to prepare students for roles in society, industry, and science. Innovation at KIT connects scientific findings to practical applications, benefiting society, economic prosperity, and the environment.

KnowledgeAgent specializes in market intelligence, offering expertise in business research, strategic analysis, data analytics, and integrated Market Intelligence Solutions. Their pharma & healthcare team supports global teams in analyzing trends, products, markets, and competitors. With analysts educated at top universities and extensive industry experience, KnowledgeAgent uses advanced software and diverse sources to address strategic questions. The company is a trusted partner of global consultants, multinational corporations, and mid-market firms.

The Bergstrasse district, the southernmost in Hesse, is uniquely a member of both the Rhine-Main and Rhine-Neckar metropolitan regions. This dual membership makes it a sought-after business location, combining the advantages of both regions. Besides its appeal for businesses, the district is also valued as a residential area due to its natural beauty and geographical diversity.

KyooBe Tech develops innovative production technologies for biopharmaceuticals, combining robotics, automation, and biotechnology to create sustainable solutions. Key areas include pathogen inactivation and automated production of personalized cell and gene therapies. With a strong affiliation to Bausch+Ströbel SE, KyooBe Tech launched eFIT in 2024 for pathogen inactivation via low-energy electron irradiation. Their MOSAIC system improves personalized cell therapy production, reducing costs and increasing efficiency.

LBBW Venture Capital GmbH invests in technology-driven companies in life sciences, digital transformation, and fintech in the DACH region since 1998. In life sciences, it focuses on drug development, diagnostics, medtech, bioanalytics, and digital health. LBBW VC supports growth-stage companies with investments from €0.5M to €3M and has capital for follow-on rounds. It also offers management expertise and connects start-ups with medium-sized and large companies via the LBBW corporate network.

!LEVA specializes in guiding pharmaceutical companies through the complexities of development, from company foundation to early clinical studies. Over the past 25 years, the !LEVA management team has co-founded and successfully managed nearly a dozen companies, mainly in the pharmaceutical sector, while supporting numerous biotech companies in corporate and product development. !LEVA Sciences was founded to share this expertise with innovative life science projects, helping companies achieve success through hands-on involvement and C-level leadership when needed.

Lonza is a global partner for the pharmaceutical, biotech, and nutrition markets, enabling healthier solutions by supporting the development of innovative medicines. Combining technological insight with manufacturing and scientific expertise, Lonza helps customers commercialize healthcare innovations. Founded in 1897 in the Swiss Alps, Lonza now operates across five continents with about 16,000 employees. In 2021, the company generated CHF 5.4 billion in sales and CHF 1.7 billion CORE EBITDA.

Marcommotion offers strategic consulting and tailored marketing communication services for life science companies and institutions. Founded in 2015 by Dr. Susanne Kuhlendahl, with over 20 years of expertise in life science marketing, the company is well-versed in the industry’s media, sales channels, and communication tools. Marcommotion provides strategic advice on market entry and positioning in competitive sectors like drug discovery, diagnostics, biotech, and medtech, supported by an established partner network.

The Max Planck Institute for Medical Research, founded in 1927, has thrived through notable scientists working at the intersection of physiology, physics, chemistry, and biology. The institute focuses on real-time observation and manipulation of macromolecular interactions in living cells, exploring health and disease. Its four departments specialize in atomic structures (Ilme Schlichting), optical nanoscopy (Stefan W. Hell), reporter molecules (Kai Johnsson), and cellular biophysics (Joachim Spatz). The institute is part of the Max Planck Society and one of four in Heidelberg.

Medea Biopharma GmbH focuses on developing sustainable, eco-friendly antibacterial solutions using bacteriophages (phages) to address antimicrobial resistance. Phages, natural bacterial killers, are highly specific and cause no side effects. These innovations aim to replace traditional antibiotics, copper-based solutions, and pesticides, offering effective, environmentally responsible methods to combat harmful bacteria across human health, animal welfare, and agriculture.

Value Data GmbH turns data into value for companies and society. By applying digital technologies, it integrates data understanding into business strategies and processes. Using machine learning and deep learning, Value Data incorporates intelligence into customer products and solutions, guided by modern software development methods, continuous delivery, and social responsibility. Medical Brick, part of Value Data GmbH, aims to accelerate diagnostics and support drug screening and discovery through in-depth analyses of microscopic images.

Medicalvalues transforms medical data points into actionable diagnostic insights. Its AI-based solution supports complex diagnostic decision-making and enables integrated diagnostics by aggregating and contextualizing interdisciplinary diagnostic data. Combining real-time patient information (e.g., symptoms, lab results, imaging) with research knowledge, the system recommends suspected diagnoses, differential diagnoses, and next diagnostic steps. Medicalvalues also provides modules for next-gen order entry, automated report generation, data/workflow management, and AI research infrastructure.

Merck KGaA, Darmstadt, Germany, is a global science and technology leader in healthcare, life science, and performance materials. With around 58,000 employees, the company aims to improve lives through innovations in gene editing, disease treatment, and smart devices. In 2021, Merck KGaA generated €19 billion in sales across 66 countries. While holding global rights to the “Merck” name, it operates in the U.S. and Canada as EMD Serono (healthcare), MilliporeSigma (life science), and EMD Electronics. Founded in 1668, the company remains majority family-owned.

Since 1986, MetaSystems has been developing systems for automated microscopic imaging. With 30 years of experience in image analysis and automated microscopy, the company has built an innovative product portfolio. Central to MetaSystems’ success is its “MetaSystems Spirit,” a human-centered approach emphasizing customer satisfaction, collaboration, and global partnerships. Customer service, expert training, and direct communication are key elements of the company’s philosophy, fostering a sense of community among its worldwide partners.

mfd, which stand for Models, Facts and Data, uses high-quality animal models to provide reproducible data, supporting clients in achieving research goals. Founded in 2004 from the University of Mainz, the team has extensive expertise in biotechnology, veterinary medicine, diagnostics, pharmacology, and pathology. mfd specializes in health monitoring, cryopreservation, animal husbandry, immunization, and contract research on small rodents and pigs.

Nanobot OÜ Communication is an award-winning scientific communication agency specializing in marketing and communication strategies for life science companies. They offer services in strategic content creation, targeted marketing, and design to ensure scientific breakthroughs are well-represented and effectively communicated. Nanobot excels in creating engaging digital content, effective slide decks, and impactful presentations and booth materials for scientific events.

NEC Bio Therapeutics focuses on developing personalized cancer vaccines, with NECVAX-NEOl as its main product. This clinical-stage oral tumor vaccine uses live, attenuated bacteria carrying plasmid DNA to encode tumor-specific neoantigens. These neoantigens are identified using Next Generation Sequencing (NGS) of patient-specific tumor biopsies and analyzed with the NEC Immune Profiler Software. NECVAX-NEOl is in various clinical trials for solid tumors, from early treatment to metastatic cases. The platform’s plug-and-play technology supports rapid production and targets a wide range of neoantigens, suitable for personalized and shared approaches

NEC Laboratories Europe, based in Heidelberg, Germany, was founded in 1994 to support NEC Group’s European customers. The lab focuses on research, development, and standardization in data science, AI, blockchain, platform security, 5G networks, and IoT platforms. These efforts contribute to NEC Group’s Solutions for a Better Society in digital health, communication infrastructures, safer cities, and public services.

NEUWERK offers comprehensive legal expertise, thinking outside the box to advise and represent clients. Based in Hamburg and operating internationally, NEUWERK’s life sciences services cover pharma, biotech, and medtech. They develop protection and licensing strategies, negotiate research partnerships, and provide support for pharmaceutical product development, manufacture, and marketing. They also offer industry-specific advice on M&A deals and corporate law matters.

The Natural and Medical Sciences Institute (NMI) at the University of Tübingen conducts research at the interface of bio- and material sciences. NMI supports health care and industrial sectors in R&D and services, focusing on drug development, personalized medicine, and materials functionalization. Their work spans Pharma, Biotech, Biomedicine, and Materials Sciences, with key services in analytics and electron microscopy. NMI is also recognized for its start-up incubator concept in biotechnology and materials science.

Novaliq develops and commercializes first-in-class ocular therapeutics using EyeSol®, the world’s only water-free technology for ophthalmology. EyeSol® improves corneal residence time and bioavailability, offering faster onset and eliminating preservatives. With a focus on dry eye disease (DED), Novaliq provides a leading portfolio addressing the unmet needs of millions of patients with eye diseases.

Nuvalore GmbH bridges science and quality to deliver top laboratory services for pharma and life sciences. Specializing in analytical quality by design, method development, validation, and quality control, their experienced team uses advanced technologies to meet high standards. Nuvalore ensures better product and process understanding, helping clients bring safe products to market.

OCCIDENT invests in deep tech start-ups focusing on spin-offs from scientific research that enable concrete solutions for different societal challenges. As an owner-managed venture capital investor with offices in Munich and Zug, OCCIDENT supports start-ups in the life sciences and industrial tech sectors from the seed stage onwards and enables founding teams to achieve outstanding results. With a strong entrepreneurial mindset, OCCIDENT invests its own money and accompanies their portfolio companies over the long term.

Octapharma Biopharmaceuticals, founded in 1997, focuses on developing recombinant protein pharmaceuticals as modern alternatives to plasma products. Their goal is to create therapeutic proteins that closely resemble native human proteins for optimal tolerability and function. The company strives for improved compatibility, longer half-life, and convenient administration routes. Octapharma follows strict GMP standards in production, storage, and laboratories to ensure top-quality products for patients.

OLS – OMNI Life Science accelerates cell research with smart, reliable, and user-friendly technologies for life sciences and biotechnology. Their products are used in public, private, pharmaceutical, and biotech labs. The portfolio includes instruments, media, reagents, consumables, and services for Cell Counting, Culture, Imaging, Flow Cytometry, and Analysis. OLS supports researchers throughout the entire process, from conception to conclusion. They also offer instrument maintenance and provide training courses through their Life Science School.

Owkin, founded in 2016, is an AI-powered life science company focused on advancing therapeutics in oncology, immunology, and cardiology. Owkin’s platform connects top medical centers and patient datasets using privacy-preserving federated learning technologies for decentralized AI model training. The company uses AI to understand variations in drug efficacy, enhance drug development, and identify optimal treatments for individual patients.

PAICON, founded by physicians and researchers in Heidelberg, creates a digitized environment for entrepreneurship, global collaboration, and certified medical product development, focusing on academia and healthcare. The company develops a secure GDPR-compliant medical cloud and AI diagnostic algorithms, certified under SaMD and IVD/MDR protocols. PAICON simplifies processes, allowing medical researchers to focus on improving lives through data.

Panosome GmbH uses its proprietary VAST technology to generate antibodies for challenging disease targets, focusing on cancer with high medical need. Their platform unlocks antibodies to small molecules, peptides, and proteins with high specificity, reducing side effects. Panosome targets pancreatic cancer through monoclonal antibodies against tumor-specific carbohydrates (e.g., MUC1) and addresses midline glioma, a rare aggressive brain cancer in children, by targeting mutations.

PEPperPRINT, a biotech spin-off from the German Cancer Research Center, offers the PEPperCHIP® Peptide Microarray platform with high content flexibility and peptide diversity. Custom peptide microarrays can be created quickly using proprietary laser printing technology. Applications include epitope mapping, serum profile and kinase signature analysis, and peptide drug development. PEPperMAP® services provide epitope mapping and serum profiling, covering epitope substitution scans and multiplexed mappings.

HABIOC GmbH offers advanced tools for drug screenings, focusing on efficiency and reduced animal testing. Key products include: – PermeaPad: Simulates human barriers to predict drug uptake without animal tests. – SpecPlate: Measures drug concentrations quickly and reliably in high-throughput settings using UV/Vis spectroscopy. These tools address complex lab challenges and enhance analysis.

Phialogics, a spin-off from Fraunhofer ITMP, is a preclinical biotech company developing therapeutics for autoimmune diseases. Using advanced protein engineering and immune system expertise, Phialogics creates bi-specific biologics to restore immune tolerance and prevent tissue damage. Their focus is on autoimmune disorders with significant unmet needs.

PHYTOMIC GmbH develops medicines from natural extracts, using expertise in solubilization and Multi-Omics tools to target complex pathways. Their approach builds on traditional medicines, addressing issues like instability and poor solubility. By overcoming these barriers, PHYTOMIC aims to create new medicines and dietary supplements and is seeking development partners.

PL BioScience, founded in 2015 as an RWTH Aachen University spin-off, specializes in cell culture supplements from human platelets. Their ELAREMTM technology provides tailored supplements with rich growth factors, supporting cell growth under GMP conditions. The products are used in academic and pre-clinical research and cellular therapy, ensuring safe transitions from lab to patient.

PlantShield GbR develops and produces biological fungicides using plant extracts, drawing inspiration from nature to create safe and sustainable products. The focus is on plant protection against fungal diseases. If efficacy tests are successful and toxicity tests (to humans, soil, and the environment) are negative, the product has global market potential for both greenhouse and field crops. The approach involves ‘biomimetics’—utilizing biological systems and their functional principles to create biofungicides, improving quality of life.

Polysciences, Inc. is a manufacturer of fine and specialty chemical materials for industrial, consumer, academic research and biotechnology applications. For over four decades Polysciences, Inc. has developed and manufactured a wide range of products for customers working within the life sciences, histology, microsopy, immunology, monomer and polymer, microparticles, electronic chemicals and personal care markets.

PROGEN, founded in 1983 by Heidelberg scientists, manufactures high-quality antibodies for biomedical research. The company aids global scientists in advancing biopharmaceuticals and diagnostics, aiming to make new therapies safe and affordable. The PROGEN team, including AAV experts, works with specialists worldwide. Beyond antibodies and AAV gene therapy tools, PROGEN focuses on understanding and solving challenges in academic research and biotechnology.

Promega, a global leader since 1978, offers over 4,000 products in genomics, protein analysis, cellular analysis, drug discovery, and genetic identity. The company provides innovative solutions and technical support to life scientists across academic, industrial, and government settings. Promega’s products aid in fundamental research, disease diagnosis, therapeutic discovery, and DNA testing. With about 100 employees, Promega GmbH, a subsidiary since 1997, distributes Promega products in Germany, Austria, Poland, and Eastern Europe.

ProtaGene CGT GmbH, formerly GeneWerk GmbH, is part of ProtaGene, a leading analytic CRO for the biopharmaceutical and cell and gene therapy industries. Known for setting standards in vector safety and integration site analysis, ProtaGene has over 20 years of experience supporting the development of gene therapies, including Glybera®, the first gene therapy drug approved in the West. The company’s strong bioinformatics and R&D capabilities help clients navigate regulatory safety requirements from research to commercialization.

RACON GmbH supports pharmaceutical companies in drug development, approval, and maintenance. Founded by Dr. Hans Rensland, RACON offers expertise across various drug forms, including tablets, powders, eye drops, antibodies, and cell and gene therapies. The company handles EU processes like CTAs, scientific advice, and MAAs, as well as U.S. INDs, scientific advice, and NDA/BLAs. RACON also assists with approval renewals and changes, providing in-house eCTD submission creation for all CTD modules.

Recherche und Beratung, Henrik Schreiber, offers expert information search services in patents, designs, trademarks, and literature. The team of professionals specializes in chemistry, life sciences, technology, and patents. Services include novelty, state-of-the-art, opposition, and freedom-to-operate searches, as well as regular alerts on competitors and topics. The company also provides chemical structure and biosequence searches. Founded in 2005, Recherche und Beratung is based in Heidelberg.

RHEACELL, a clinical-stage biopharmaceutical company based in Heidelberg, Germany, specializes in innovative stem cell therapies for severe inflammation-driven diseases with high unmet needs. Founded in 2012, RHEACELL aims to help patients with rare diseases who lack other therapy options. Their proprietary ABCB5+ mesenchymal stem cell therapy targets inflammation and aids recovery by treating external and internal wounds. The company’s broad pipeline focuses on expanding clinical development and market access for rare and orphan diseases.

The Rhine-Neckar District is a top location in Germany, known for its excellent infrastructure and proximity to Mannheim and Heidelberg universities, which provide a skilled workforce. Home to global companies like SAP and GELITA AG, as well as numerous SMEs, it supports entrepreneurs with strong business development and subsidy knowledge. With 54 towns and over 554,000 residents, it forms the economically robust Rhine-Neckar metropolitan region, the most populous district in Baden-Württemberg.

Rittershaus stands out as a unique commercial law firm, viewing itself as a partner in corporate issues rather than just advisors. With offices in Mannheim, Frankfurt, and Munich, its team of lawyers and notaries provides comprehensive advice across corporate law, M&A, employment law, intellectual property, and regulatory matters. Additionally, Rittershaus assists clients with favorable tax strategies for asset and corporate succession.

RLP AgroScience GmbH, a non-profit owned by Rhineland-Palatinate, comprises two divisions: AlPlanta – Institute for Plant Research and the Institute for AgroEcology. AlPlanta focuses on environmental protection by developing non-toxic pesticide alternatives and optimizing plant traits through resistance breeding. It collaborates with universities like Mannheim, Heidelberg, and Hohenheim, and partners with research institutions and businesses on national and international projects.

Roche, a global leader in pharmaceuticals and diagnostics, advances personalized healthcare by combining its strengths in both areas. Roche excels in oncology, immunology, infectious diseases, ophthalmology, and central nervous system disorders. It also leads in in vitro diagnostics and cancer diagnostics, and is a frontrunner in diabetes management. Founded in 1896 and headquartered in Basel, Roche operates in over 100 countries and employs about 94,000 people. The company is recognized for its sustainability and has 30 essential medicines listed by the WHO.

Sanofi is dedicated to supporting people through their health challenges. Sanofi is a global biopharmaceutical company focused on human health. The company prevents illness with vaccines, provide innovative treatments to fight pain and ease suffering. Sanofi stands by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Schrödinger provides advanced molecular simulations and enterprise software to enhance drug discovery and materials design. With a growing pipeline and co-founded biotech companies like Nimbus Therapeutics and Morphic Therapeutic, Schrödinger collaborates across biotechnology, pharmaceuticals, chemicals, and electronics. Founded in 1990, the company invests in research and has made significant breakthroughs in drug discovery and materials science. Schrödinger employs nearly 425 people and operates in the U.S., Europe, Japan, and India, with partners in China and Korea.

ScienceValue Heidelberg GmbH (SVH) was funded in November 2019 and is a consulting company for academic technology transfer. The company is a wholly owned subsidiary of Heidelberg University. The goal of SVH is to create a bridge between university research and industrial development. The core of the company is services related to the exploitation of intellectual property from university-related institutions.

Sciomics GmbH was founded in the spring of 2013 as a spin-off company of the German Cancer Research Center (DKFZ) by Dr. Christoph Schröder and Dr. Jörg Hoheisel. Since 2003, Sciomics’ team has gained experience with production and application of antibody microarrays as a tool for analysing complex protein samples. With this background, Sciomics is able to offer complete analysis of its costumers’ samples with standardised as well as customised arrays.

SCOPE International is an independent full-service CRO based in Mannheim, Germany, with over 250 employees in Europe and the USA. Operating in more than 30 countries through local offices and partners in Asia-Pacific, South America, Scandinavia, and the Middle East, SCOPE offers tailored services for small to medium-sized pharmaceutical, biotech, and medical device companies. Their strengths include reliable expertise from early-stage to late-phase development, long-term stability, and a high degree of efficiency and flexibility.

Singleron aims to push the boundaries of single-cell analysis with its comprehensive multi-parallel single-cell sequencing solution. Their SCOPE technology handles tissue sample collection, preparation, and automatic RNA analysis at the single-cell level. By providing innovative gene expression and multi-omics solutions, Singleron empowers clinical researchers to transform insights into cancer, immunological, and neural disorders into practical medical guidance.

The Sino German Hi-Tech Park (SGHTP) is Germany’s first German-Chinese science and technology park, fostering bilateral cooperation. It provides a platform for entrepreneurs, business associations, and institutions to collaborate on smart factories, IT, e-mobility, and life sciences. SGHTP links experts and decision-makers from both countries via two Heidelberg centers: the “German Offshore Center” for Chinese economic zones and the “China Gateway Center” for German market entry. Located in the “TechTower,” with plans for a new innovation campus, SGHTP bridges Germany’s INDUSTRIE 4.0 and China’s CHINA 2025 strategies.

Skylabs Development & Construction GmbH, based in Heidelberg, is the project developer and asset manager for the Max-Jarecki-Foundation. Specializing in office and laboratory real estate, Skylabs has been developing sites in Heidelberg’s Bahnstadt district since 2009. The company handles planning, construction, marketing, maintenance, and management of properties in its portfolio, collaborating with various local and international partners.

SPT Labtech has been transforming the way scientists work for over 25 years by pioneering automation in liquid handling, sample preparation, and sample management. Their solutions are trusted by labs globally to streamline lab tasks, reduce human error, and ensure precise, consistent results. Using positive displacement technology, they enable ultra-low volume accuracy in liquid handling, extending the use of precious reagents and samples. Their automated systems simplify sample storage and organization, while their cryo-EM tools uncover new structural biology insights through enhanced sample preparation.

Heidelberg is a city of science and has been for many years. Germany’s oldest university city has ten higher education establishments and over 38,000 students. Education starts at an early age: Heidelberg has the country’s best childcare provisions. Its universities are also world-beaters: academic staff based here have won no fewer than 56 Nobel prizes. As recently as June 2012, Heidelberg University was again awarded ‘elite establishment’ status under Germany’s Excellence in Higher Education initiative. An impressive one in three of all Heidelbergers have a university qualification.

With a population of more than 300,000 made up of people from over 160 different nations, Mannheim is not only the second largest city in Baden-Württemberg: it is also wonderfully diverse, lively and colourful. A big city, a metropolis in which you can feel at home, characterised on the one hand by unpretentious authenticity and on the other by multiculturalism. With 17 city districts – the majority of which are located close to the water – and a city centre laid out in a grid of squares, Mannheim is the metropolitan region’s most important city.

SURFACtoBioTech is transforming biotechnology services with a focus on efficiency and sustainability. They specialize in droplet-based microfluidics, offering custom chemical solutions and user-friendly, plug-and-play instruments. Their mission is to advance biotechnologies, reducing environmental impact and resource usage while enhancing laboratory efficiency. Join them in pioneering a more sustainable future in biotechnology.

Tcelltech GmbH, a German clinical-stage biotech spin-off from DKFZ Heidelberg (2022), develops immunotherapies to cure cancer. Their lead product, “UNIPACT,” is a personalized T-cell therapy with broad cancer potential, utilizing two platforms: the AI-based bioinformatics platform IMPACT for T-cell receptor identification and the novel non-viral gene delivery system “nanoSMAR.” Tcelltech is seeking partners for licensing nanoSMAR and accelerating its cancer vaccines, targeting IDH-1 and H3, which are in Phase I trials.

The Heidelberg Technology Park, managed by Technologiepark Heidelberg GmbH (a joint venture of the City of Heidelberg and the Rhine-Neckar Chamber of Commerce), fosters rapid growth in science and technology. It hosts startups, small businesses, research facilities, and global players, supporting a dynamic ecosystem from R&D to production. Covering 6.6 ha and over 80,000 m² of lab and office space, it is a key medical and tech hub in Germany, accommodating biotech, medical technology, life sciences, and IT industries.

Technologiepark Mannheim GmbH (TPMA), a 100% subsidiary of L-Bank, was founded in 2016 and invests in the Mannheim Medical Technology Campus (MMT Campus). Located near the University Medical Centre Mannheim, the park supports the development of new medical technologies and products. TPMA handles development, realization, operation, and marketing, offering an ideal location for both established companies and startups on the MMT campus.

TET Systems, founded by the inventors of Tet Technology, holds essential patents on this widely used method for controlling gene expression in eukaryotic cells. Applied in various settings from early discovery to gene therapy, Tet Technology has proven effective in both in vitro and in vivo applications. TET Systems aims to enhance its IP portfolio by acquiring and in-licensing innovative R&D technologies from third parties.

The Cultivated B. (TCB) is pioneering biotechnology and bioengineering to advance plant and cell-based alternative proteins. TCB’s multinational team uses cellular agriculture, precision fermentation, and innovative bioreactor technologies to impact the cultivated meat, food production, and personal care industries. TCB’s R&D supports large-scale production of alternative proteins and helps its parent company, InFamily Foods, transition to a fully integrated, sustainable food producer. TCB is committed to minimizing resource use for a sustainable future.

Thermo Fisher Scientific, a global leader in serving science, boasts annual revenues over $25 billion. The company’s mission is to help customers make the world healthier, cleaner, and safer. Thermo Fisher supports diverse needs from accelerating life sciences research to improving patient diagnostics and increasing lab productivity. With over 75,000 employees, Thermo Fisher offers innovative technologies and services through brands like Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

Trans-Duodenal Concepts GmbH has developed an endoscopic implant to treat Type 2 diabetes, obesity, and fatty liver diseases. This implant covers the upper small bowel, reducing nutrient absorption and improving diabetic metabolism, while also addressing obesity and NASH. The device is produced using advanced technologies like blow molding of ultrathin polyurethane foils and is protected by globally approved patents. The company integrates clinical expertise with plastic technologies and regulatory know-how.

The Technical University of Darmstadt, founded in 1877, excels in science and innovation. Addressing global challenges in energy transition, Industry 4.0, and AI, the university excels in cutting-edge research. Located in the Frankfurt-Rhine-Main region, it is one of Germany’s most international universities, committed to European values. Its research spans Energy and Environment, Information and Intelligence, and Matter and Materials, promoting interdisciplinary collaboration with society, business, and politics.

The patent attorneys and attorneys at law at ULLRICH & NAUMANN have been representing their clients in all areas of intellectual property since 1929 . The firm’s main focus and specialist areas are patent law, utility model law, trademark law, design law, employee inventions law and more. ULLRICH & NAUMANN also has particular expertise in the area of copyright law and IT law.

Valency Communications, founded as a senior advisory firm for life sciences, supports the European biotechnology ecosystem. Combining expertise in science, life science journalism, IR, and corporate communications, Valency advises biopharma leaders. While strategic communications can’t fix science, it impacts all aspects of a biopharma company’s success. Effective communication helps companies attract support and progress from seed funding to IPO, preclinical trials to market approval, and from lab to “Best Places to Work.”

VectorBuilder offers a revolutionary platform for vector design, custom cloning, and virus packaging. It provides additional molecular biology services such as stable cell line generation, BAC modification, and mutagenesis. The user-friendly web platform, VectorBuilder.com, allows researchers globally to design and order vectors and viruses quickly. With an extensive component database, VectorBuilder reduces costs and turnaround times. Its intuitive interface and competitive pricing have made it a favorite among academic and industry leaders.

VERAXA Biotech GmbH is a clinical-stage company pioneering cancer therapies with next-generation antibody-based treatments. Utilizing proprietary tools, including high-throughput droplet-based microfluidic technology and advanced antibody conjugation platforms, VERAXA develops antibody-drug conjugates (ADCs) and innovative antibody formats. Its conjugation platform features genetic code expansion and click-chemistry techniques for precise payload attachment. VERAXA is at the forefront of groundbreaking cancer therapy solutions.

The VCI represents the economic policy interests of around 1,700 German chemical companies and German subsidiaries of foreign corporations vis-à-vis politics, public authorities, other sectors of the economy, science and the media. The VCI represents more than 90 percent of German chemistry. The industry made in 2018 around 204 billion euros and employed 462,000 people.

WISTA, founded more than 30 years ago, is a medium-sized, independent auditing and tax consulting firm based in Mannheim with branches in Speyer, Constance and Radolfzell on Lake Constance. Consulting services can not be reduced to isolated solutions, since most tasks are far too complex. That is why accountants, tax consultants, lawyers and management consultants work together across disciplines at WISTA. Because the company wants optimal results for its clients in all points! Since its foundation, WISTA advises and supports clients holistically through the WISTA consulting network.

WMT develops small molecules to target late-stage solid cancers by addressing the Warburg metabolism, characterized by high glycolysis and lactate production in tumors. The company’s anti-Warburg Warheads (AWWs) work by reducing this specific cancer metabolism, decreasing lactate levels in the tumor microenvironment. This approach not only inhibits tumor growth but also reactivates the immune system against the tumor. Currently in the preclinical stage, WMT’s proprietary compounds have demonstrated these effects in vivo.

World Courier, now a part of Cencora, is a global specialty logistics company that designs world-class supply chain programs in complete alignment with customers’ business goals. The company delivers ultimate peace of mind for the transport and storage of time- and temperature-sensitive products. For more than 45 years, only World Courier has delivered the unsurpassed knowledge, global reach and flawless supply chain execution needed to become the most trusted specialty logistics company in the world.

YUMAB develops fully human antibodies from target to lead globally. Its platform covers all stages of development, from discovery with one of the world’s largest natural human antibody libraries (>10e11) to engineering and optimization. YUMAB’s antibodies feature natural, near germ-line sequences, ensuring low immunogenicity. Advanced selection technologies pre-design properties like cross-reactivity, with high success rates for challenging targets. Optimization techniques streamline the path to lead candidates for diverse antibody formats, including IgG, Fab, and ADCs.

Zamann supports companies of all sizes in digitalization, compliance, and scalable quality management. Specializing in Life Science Quality Consultancy, Zamann partners with the pharmaceutical and medical device industries to offer services including: Training and Coaching, Management Consultation, Global Project Management, cGxP Compliance, Pharma Software Development, Validation and Qualification.

ZentriForce Pharma is an analytical service provider specializing in hydrodynamic techniques for biopharmaceuticals, focusing on gene therapy and biosimilarity studies. Utilizing state-of-the-art equipment, ZentriForce collaborates with experts like Professor Stephen E. Harding and Professor Dr. Helmut Cölfen to advance technology and theory. The company is committed to meticulous, reliable work and adheres to strict quality guidelines, offering extensive experience and innovative approaches in analytical services.

The Rhine-Neckar Metropolitan Region is a dynamic area known for its successful industries, renowned research facilities, and vibrant cultural scene. The region boasts a strong alliance of industry leaders, universities, and cultural institutions, making it one of Germany’s most attractive places to live and work. With a diverse range of jobs and a wealth of cultural and natural attractions, the region offers its 2.4 million residents an exceptional quality of life. The open-minded and creative spirit of its people ensures continued prosperity and growth.